Bharat Parenter. — Q4 FY26 earnings call

Call held 19 May 2026

Management summary

Bharat Parenterals Limited reported a transformative FY26, marked by significant EBITDA expansion despite flat consolidated revenue. This was primarily driven by Innoxel Lifesciences turning EBITDA positive and Varenyam Healthcare achieving profitability. While the standalone business faced headwinds from deferred orders and production upgrades, the company secured key regulatory clearances for Innoxel, positioning it for commercial inflection in FY27. Management provided cautious but confident guidance for FY27 across all segments, emphasizing operational leverage and pipeline progression.

Highlights

  • Consolidated EBITDA for FY26 was INR 15.8 crores, a 485% expansion from INR 2.7 crores last year, driven largely by Innoxel's improved performance.

  • Innoxel Lifesciences revenue grew by 174% to INR 72.4 crores in FY26 and achieved EBITDA positivity of INR 1.4 crores in Q4 FY26.

  • Varenyam Healthcare turned profitable in FY26 with revenue growth of 13.7% to INR 58.4 crores and EBITDA of INR 2.5 crores.

  • Standalone business maintained 9% EBITDA margin and 6.8% PAT margin despite a 23% revenue decline, and reduced finance cost by 28%.

  • Innoxel received US FDA establishment inspection report clearance and FAMHP (Belgian regulator) clearance for EUGMP with zero critical/major observations, enabling commercial supply to US and European markets.

Concerns

  • Standalone business revenue declined by 23% in FY26 to INR 234 crores from INR 304 crores last year due to deferred export tenders, stepping away from low-margin volume businesses, and production line upgrades.

  • Varenyam Biolifesciences commercialization timeline shifted from FY27 to Q4 FY29 due to geopolitical disturbances causing a 3-month delay.

  • EUGMP inspection for standalone facilities in FY27 is expected to cause 'certain disruptions' and production days loss.

Key financials

2 periods

Headline

  • Consolidated Revenue
    ₹345.4 Cr
    YoY +1.6%
  • Consolidated EBITDA
    ₹15.8 Cr
    YoY +485%
  • Consolidated PAT
    ₹-27.3 Cr

Q4

  • Consolidated Revenue
    ₹99.6 Cr
    QoQ +52.8%

What they filed

Q1 FY27: revenue down 19.2%, net profit down 309.2% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue72 72 104 116 65 −10%65 −10%100 −4%94 −19%
EBITDA-8 4 2 14 1 +111%2 −52%-1 −123%9 −38%
Net profit-18 -8 -9 -1 -9 +51%-10 −23%-8 +14%-4 −309%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

SegmentRevenueQ4 Revenue
Standalone Business (BPL)₹234 Cr₹56.5 Cr
Innoxel Lifesciences₹72.4 Cr₹37.5 Cr
Varenyam Healthcare₹58.4 Cr₹11.6 Cr
Varenyam Biolifesciences——

Order book

high confidence

Total value

₹171 Cr

as of 2026-03-31 quantified

Execution

gives us reasonable visibility for FY '27

Cancellations & deferrals

  • deferred: A number of export tenders got deferred into the next year, orders are still ours, shipment slipped.
Order book provides reasonable visibility for the next fiscal year, despite some deferrals in the past year.

Source: Prepared remarks

Capital allocation

medium confidence
  • Capex ₹160 Cr
    • Varenyam Biolifesciences facility construction ₹160 Cr
    Our approved budget is around INR 160 crores and our CWIP at the year-end was around INR 33 crores.
  • Debt Debt disclosed
    We also reduced our finance cost by 28% and we kept other expenses tightly under control, and they came down 40% year-on-year.

Guidance & targets

Revenue

  • Standalone Business Revenue Growth Revenue · FY27 · Medium confidence 10% to 15%
    For the standalone business, we expect revenue growth of 10% to 15% with EBITDA margins in the same 10% to 15% range.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel Lifesciences Revenue Growth Revenue · FY27 · Medium confidence 35% to 45%
    For Innoxel, we expect revenue growth of 35% to 45% with EBITDA margins of 20% to 25%.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel Out-licensing Income Revenue · FY27 · Medium confidence INR 70 crores to INR 90 crores
    ...and overall out-licensing income is expected between INR 70 crores to INR 90 crores.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Varenyam Healthcare Revenue Growth Revenue · FY27 · Medium confidence 20% to 25%
    For Varenyam Healthcare, we expect revenue growth of about 20% to 25% with EBITDA margins of 8% to 13%.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Standalone Business Peak Revenue Revenue · 3-4 years away (from 2030 standpoint) · Low confidence INR 400 crores to INR 500 crores
    It is expected from the standalone business to deliver INR 400 crores to INR 500 crores of top line, but that is obviously, this will be sequential and there is, I would say, a 3-year to 4-year time before which we can expect those things to come. Always the peak revenue has been discussed from a 2030 standpoint. So I believe we are still 4 years away from that.

    — Bhahim Desai, Director, Strategy and Investor Relations

Profitability

  • Standalone Business EBITDA Margins Profitability · FY27 · Medium confidence 10% to 15%
    For the standalone business, we expect revenue growth of 10% to 15% with EBITDA margins in the same 10% to 15% range.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel Lifesciences EBITDA Margins Profitability · FY27 · Medium confidence 20% to 25%
    For Innoxel, we expect revenue growth of 35% to 45% with EBITDA margins of 20% to 25%.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Varenyam Healthcare EBITDA Margins Profitability · FY27 · Medium confidence 8% to 13%
    For Varenyam Healthcare, we expect revenue growth of about 20% to 25% with EBITDA margins of 8% to 13%.

    — Bhahim Desai, Director, Strategy and Investor Relations

Product Launch

  • Innoxel Commercial CMO Supply Start Product Launch · FY27 · High confidence Q2 FY27
    The big catalysts are first commercial CMO supply starting Q2 of FY '27 and overall two to three CMO products commercializing during the year.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel CMO Products Commercializing Product Launch · FY27 · Medium confidence two to three

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Varenyam Healthcare New Product Launches Product Launch · FY27 · High confidence 7
    ...seven new product launches including Remishot, which will be India's first made-in-India and the launch of our second division,, which will operate in gynecology.

    — Bhahim Desai, Director, Strategy and Investor Relations

Filings

  • Innoxel New Filings Filings · FY27 · High confidence 10
    Additionally, I would like to point out that there would be 10 new filings from Innoxel this year.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel First MHRA and Health Canada Filings Filings · FY27 · High confidence during the year
    ...our first MHRA and Health Canada filings during the year...

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel 505(b)(2) Product US Filing 1 Filings · FY27 · High confidence Q3 FY27
    Going forward, I would say that for this particular asset, the US bio studies once completed, the target date for filing the product would be somewhere in Q3 of this FY '27.

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Innoxel 505(b)(2) Product US Filing 2 Filings · FY27 · High confidence Q4 FY27
    And as far as the other 505(b)(2) oral liquid product is concerned, that the target date of filing is Q4 of FY '27.

    — Bhahim Desai, Director, Strategy and Investor Relations

Deals

  • Innoxel New Partner Deals Deals · FY27 · Medium confidence 20
    20 new partner deals which are targeted, out of which 10 are at advanced stages of discussions and due diligence...

    — Bhahim Desai, Director, Strategy and Investor Relations

Headcount

  • Varenyam Healthcare Field Force Expansion Headcount · FY27 · High confidence upwards of 250 people
    We expect the field force to expand upwards of 250 people...

    — Bhahim Desai, Director, Strategy and Investor Relations

New Business

  • Varenyam Healthcare Second Division Launch New Business · FY27 · High confidence gynecology
    ...and the launch of our second division,, which will operate in gynecology.

    — Bhahim Desai, Director, Strategy and Investor Relations

Timeline

  • Varenyam Biolifesciences Facility Commissioning Timeline · FY28 · High confidence September 2027
    The key milestones for this business are: commissioning of the facility in September of 2027...

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Varenyam Biolifesciences Line Validation Timeline · FY28 · High confidence March 2028
    ...line validation of manufacturing lines by March 2028...

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Varenyam Biolifesciences First Regulatory Filing (EUGMP) Timeline · FY29 · High confidence Q1 FY29
    ...our first regulatory filing under EUGMP expected to be Q1 of FY '29...

    — Bhahim Desai, Director, Strategy and Investor Relations

  • Varenyam Biolifesciences First Commercial Supply Timeline · FY29 · High confidence Q4 FY29

    Previously FY27 → Q4 FY29

    ...and subsequently our first commercial supply in Q4 of FY '29.

    — Bhahim Desai, Director, Strategy and Investor Relations

Commercialization

  • Delayed $27M Export Order Coverage Commercialization · this year (FY27) · High confidence 90%
    I would say that we would be covering 90% of that remaining 90% of the order in this year, and then there would be some spillage that we expect, which would be a smaller spillage in the next year, start of next year.

    — Bhahim Desai, Director, Strategy and Investor Relations

What to watch in Q1 FY27

Standalone Business Regulatory Inspections

FY27
Current Scheduled for FY27
Target Progress/Completion of PIC/S and EUGMP inspections

Why it matters

Successful completion of inspections is crucial for continued market access and operational stability, and will impact production days.

PIC/S and EUGMP inspection at our standalone facilities are scheduled during FY '27.

Risks & concerns

  • Regulatory Inspections and Production Disruption

    medium

    EUGMP inspection for standalone facilities in FY27 will cause 'certain disruptions' and loss of production days due to preparatory phase and actual inspections.

    Management acknowledged

  • Geopolitical Disturbances Impacting Timelines

    medium

    Current geopolitical disturbances have caused a 3-month delay in the Varenyam Biolifesciences commercialization timeline.

    Management acknowledged

  • Deferred Export Tenders

    medium

    A number of export tenders for the standalone business were deferred into the next year, causing a revenue decline in FY26, though orders are still valid.

    Management acknowledged

Q&A highlights

7 direct
Standalone Business Growth Guidance Revision Direct
I want to be straightforward with you about why this happened. There were three reasons. First, we had a number of export tenders that got deferred into the next year. The orders are still ours, the shipment slipped. Second, we made a deliberate choice to step away from some low-margin volume businesses that was not adding any value and third, and this is the one I really want you to pay attention to, we took down some of our production lines for upgradation work this year.

Analyst questioned the lower revised growth guidance for the standalone business, prompting management to detail the specific operational and market reasons for the change.

Asked by Harshit Khadka

Varenyam Biolifesciences Commercialization Timeline Shift Direct
So yes, there has been certain revisions in terms of timeline. I would also like to point out that the current geopolitical disturbance has had an impact on the, I wouldn't say too much of an impact, but we are 3 months, at least one quarter running behind on schedule as to what we had expected earlier.

Analyst identified a significant delay in the commercialization timeline for Varenyam Biolifesciences, which management attributed to geopolitical disturbances.

Asked by Harshit Khadka

Overall Cautious Guidance Direct
I believe that due to certain, I would say, earlier the guidances that were given and we were not able to deliver on those guidances for various reasons, underlying reasons that have already been discussed, this time around the guidances have been on the softer side and it is something that we feel is very, that we are very confident of achieving these guidances.

Analyst questioned the seemingly downgraded and cautious guidance across all segments, leading management to explain their focus on achievable targets given past misses and current operational realities.

Asked by Saloni Arya

Innoxel FY27 Margin Drivers (CDMO vs Out-licensing) Partial
This would be for FY '27 on the margin front at Innoxel primarily it would be due to milestone payments because though the commercial supplies will start it is -- it would still be for maybe two or at max three products and not more. So the commercial revenues that we expect be as meaningful in comparison to the licensing and milestone payments that we expect for this year.

Analyst sought clarity on the source of Innoxel's projected FY27 margins, revealing that milestone payments from licensing deals will be the primary driver, not yet significant commercial manufacturing.

Asked by Saloni Arya

Update on Innoxel's 505(b)(2) Products Direct
So both these assets are like the exhibit batches for both these assets have been completed at Innoxel and they are currently on stability. One of the asset has completed, I would say, the bioequivalence study for Europe and for US it is currently ongoing. We plan on filing this asset in Europe later this month. ... the target date for filing the product would be somewhere in Q3 of this FY '27. And as far as the other 505(b)(2) oral liquid product is concerned, that the target date of filing is Q4 of FY '27.

Analyst followed up on previously announced key pipeline products, confirming their progress towards US FDA filings in FY27, which are critical for Innoxel's future commercial revenues.

Asked by Avnish

Commercialization of $27M Export Order Direct
We expected the order in July of last year, but unfortunately, we got the orders somewhere in March first week of 2026, which got us the, which is where the main delay happened. So, the supply has started on that particular one. I would say that we would be covering 90% of that remaining 90% of the order in this year, and then there would be some spillage that we expect, which would be a smaller spillage in the next year, start of next year.

Analyst inquired about a significant delayed export order, and management provided an update on its commencement and expected execution timeline, clarifying its impact on standalone business revenue.

Asked by Avnish

Innoxel CMO Product Commercialization Timeline Clarification Direct
So, there are two products that we expect to be commercialized this year. First is expected in Q2 and the second is expected between Q3 and Q4.

Analyst sought clarification on conflicting timelines for Innoxel's first CMO product commercialization, leading management to provide a clear, updated schedule for two products.

Asked by Avnish

Profit Share in CMO Partnerships Direct
No, no. So, you have to understand that in a CMO partnership also, you get a fee. We charge a fee for our service of transferring the product in our facility, taking the exhibit batches, scale-up and exhibit batches, putting it on stability, helping in filing the product, and then once the approval comes, the commercialization happens. ... That necessarily does not mean that we are involved in the development of the product. If we are involved in the development of the product, that naturally falls into CDMO category and not a CMO category.

Analyst questioned the nature of revenue from CMO deals, clarifying that the company earns fees and milestones for services rather than a profit share from commercial sales, distinguishing it from CDMO.

Asked by Avnish

3 min read 6 chapters

Detailed narrative

FY26: A Year of Transition and De-risking

FY26 was characterized as a 'bridge year' for Bharat Parenterals, focusing on regulatory clearances, subsidiary expansion, and capacity building. Consolidated revenue remained broadly flat at INR 345.4 crores compared to INR 340 crores last year. However, the company achieved significant de-risking in its business mix, leading to a 485% expansion in consolidated EBITDA to INR 15.8 crores from INR 2.7 crores in the previous year. This improvement was largely driven by Innoxel's performance, which narrowed its EBITDA loss by INR 23.5 crores.

Innoxel Lifesciences Achieves EBITDA Positivity and Regulatory Milestones

Innoxel Lifesciences, the complex generics subsidiary, was a key growth driver, with revenue surging by 174.1% to INR 72.4 crores in FY26 from INR 26.4 crores. Crucially, Innoxel turned EBITDA positive for the first time in Q4 FY26, reporting INR 1.4 crores. The company secured US FDA establishment inspection report clearance and FAMHP (Belgian regulator) EUGMP clearance with zero critical observations, positioning it for commercial supply to the US and European markets from FY27. Innoxel signed 23 deals during the year, including 7 out-licensing and 16 CMO-CDO partnerships.

Varenyam Healthcare Turns Profitable with Strong Domestic Growth

Varenyam Healthcare, the branded domestic business, achieved profitability in FY26, with revenue growing by 13.7% to INR 58.4 crores from INR 51.4 crores last year. It reported an EBITDA of INR 2.5 crores, a significant turnaround from a loss of INR 3 crores in the prior year. The productivity per medical representative per month (PCPM) grew by 31% year-on-year to over 3.85 lakhs, and corporate hospital coverage expanded to over 7,500 institutions across 26 states. The company plans to expand its field force to over 250 people and launch 7 new products, including Remishot, and a new gynecology division in FY27.

Standalone Business Faces Headwinds, Focuses on Upgrades

The standalone business (BPL) experienced a 23% decline in revenue to INR 234 crores in FY26 from INR 304 crores last year. This was attributed to deferred export tenders, a strategic decision to exit low-margin volume businesses, and production line upgrades. Despite the revenue decline, the standalone business maintained a 9% EBITDA margin (INR 21 crores) and a 6.8% PAT margin (INR 16 crores), while reducing finance costs by 28%. The order book stands at INR 171 crores, providing reasonable visibility for FY27, with growth expected from Southeast Asia, Africa, and MENA regions.

Varenyam Biolifesciences: Long-Term Project with Revised Timelines

Varenyam Biolifesciences, a complex injectable platform targeting emerging regulated markets, remains under construction with an approved budget of INR 160 crores and CWIP of INR 33 crores at year-end. Civil works are 50% complete, and equipment procurement is 40% complete. The commissioning of the facility is now targeted for September 2027, with line validation by March 2028. The first regulatory filing under EUGMP is expected in Q1 FY29, and commercial supply in Q4 FY29, a revision from earlier FY27 timelines due to geopolitical disturbances.

FY27 Outlook: Commercial Inflection Across All Businesses

Management expects FY27 to be a year of commercial inflection. The standalone business is guided for 10-15% revenue growth with 10-15% EBITDA margins. Innoxel is projected to achieve 35-45% revenue growth and 20-25% EBITDA margins, with first commercial CMO supply starting in Q2 FY27 and 10 new filings. Varenyam Healthcare is expected to grow revenue by 20-25% with 8-13% EBITDA margins, driven by field force expansion and new product launches. The company aims for a full recovery of standalone business to FY25 numbers by FY28, and peak revenue of INR 400-500 crores in 3-4 years.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls